Recombinant Protein Production News and Research

RSS

Vaccine against malaria could be ready in 5 years

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

9 Dec 2008

Protein C levels help predict severity of illness and risk of death in ICU patients

A simple laboratory test to measure protein C - a natural anti-blood-clotting substance that also reflects the level of inflammation in the body - may offer a useful new indicator of the severity of illness and risk of death among critically ill patients.

26 Jun 2007

New hope for spinal cord injury sufferers

Spinal cord injury (SCI) is one of the most significant forms of neurotrauma with major economic and social impact.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

New protein structure found - important for drug discovery

Understanding and replicating the diverse ways in which cellular proteins fold and interconnect is key to understanding life processes and major disorders, such as Parkinson's disease.

15 Nov 2006

Anti-cancer antibodies produced in chickens

A team of researchers have produced the first fully functional, human sequence monoclonal antibodies (mAbs) in chickens.

29 Aug 2005

Artificial cobweb proteins for medicine

A unique material based on cobweb proteins is being created by Russian researchers of the State Research Center of Russian Federation GosNIIgentics, Scientific Research Center “Coal-Chemical Fiber”, State Research Center of Applied Microbiology in cooperation with their colleagues from Michigan University with support form the International Science and Technology Center (ISTC) (project 1033.2).

30 May 2005

Generex Biotechnology receives Australian patent for vaccine technology to fight cancer and pandemic influenza

Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Express is designing and testing such vaccine peptides for the control of cancer and infectious diseases with a particular focus on the pandemic H5N1 influenza, which has been reported in South East Asia.

26 Apr 2005

Genzyme begins gene transfer trial for peripheral arterial disease

Genzyme Corporation announced today that the first patient has been treated in a new phase 2 clinical trial examining the safety and effectiveness of locally delivered gene transfer for patients with peripheral arterial disease.

24 Feb 2005

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

New analysis from Frost & Sullivan, Strategic Analysis of the World Plant Molecular Farming Market, reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004. It is likely to reach USD 98.2 billion by 2011.

17 Jan 2005

New protein discovered holds promise for use in medicine and nanoscience

Researchers at the Hebrew University of Jerusalem have succeeded in discovering and isolating a new protein from the poplar tree with special structural and qualitative characteristics that could have consequences for development of future nanocapsules for drug delivery to cancer cells.

5 Jan 2005

Vaccinating mice against Lyme disease could help reduce the risk of transmission of the disease to humans

Vaccinating large populations of white-footed mice against the bacterium that causes Lyme disease could help reduce the risk of transmission of the disease to humans, says a study supported by the National Institute of Allergy and Infectious Diseases (NIAID).

14 Dec 2004

Malaria vaccine candidate looks extremely promising

In a proof-of-concept study published this week in The Lancet, researchers report that GlaxoSmithKline's RTS,S/AS02A malaria vaccine candidate protected a significant percentage of children against uncomplicated malaria, infection, and even severe forms of the disease for at least six months.

16 Oct 2004

Ways to economically recover recombinant proteins from transgenic tobacco

The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.

12 Aug 2004